Jomana Musmar and Aula Abbara discuss AMR market failures, One Health surveillance, and regulatory gaps
Summary
Jomana Musmar and Aula Abbara argue that antimicrobial resistance (AMR) is an underfunded, reactive crisis driven by market failures where venture capital timelines mismatch FDA approval cycles. They claim AMR mortality is vastly undercounted because deaths are attributed to primary conditions rather than sepsis, and that current broad-spectrum antibiotic use accelerates resistance. The speakers highlight how conflict, climate change, and weak governance in regions like Syria exacerbate AMR through unregulated agricultural and veterinary use. They propose value-based pricing, grassroots education, and integrating antibiotic demand into other medical fields like oncology to create sustainable markets.
Key takeaways
- 1 Abbara notes ~80% of AMR mortality occurs in low-resource settings, yet drug companies target the Global North where patients can afford treatments, creating a misalignment between burden and commercial incentive.
Unidentified speaker (speaker_2) · 19:39
- 2 Speaker_0 claims even organic produce in the US has degraded in quality, suggesting 'organic' labeling may not guarantee nutritional integrity.
Unidentified speaker (speaker_0) · 37:24
Episode sections
- 0:00 – 1:18
Introduction and One Health Concept
Lori Ellis introduces One Health, defining it as the interaction between water, environment, animals, humans, and agriculture, framing the discussion around AMR.
- 1:18 – 5:07
Reactive Society and Global Preparedness
Musmar argues society is reactive, citing rapid loss of attention after the Russia hantavirus outbreak, and emphasizes the need for threat-agnostic systems and global data sharing hindered by political tensions.
- 5:07 – 11:08
AI, Conflict, and Emerging Threats
The host asks about AI risks; Musmar and Abbara argue the immediate threat is AMR acceleration due to conflict, climate change, and targeting of healthcare infrastructure.
- 11:08 – 15:31
The Funding and Market Failure for Antibiotics
Musmar explains AMR funding is low because it is a complex 'enterprise' problem, and companies go bankrupt because the market does not value niche antibiotics enough to sustain them.
- 15:31 – 20:24
Complexity and Mortality Undercounting
Abbara highlights AMR as an insidious, invisible threat vastly undercounted in mortality statistics because deaths are attributed to primary conditions like cancer rather than resulting sepsis.
- 20:24 – 24:50
Value Proposition and Morbidity
Musmar argues the market fails because antibiotics are undervalued and overused, stressing the need to account for morbidity and economic losses associated with resistant infections.
- 24:50 – 27:23
Investment Horizons and Regulatory Timelines
Musmar states venture capital is unsuitable for AMR due to the 5-year return expectation versus the 10-year FDA approval timeline, calling for proactive investment and value-based pricing.
- 27:23 – 36:24
Warfare, One Health, and Surveillance Gaps
Abbara and Musmar discuss how conflict accelerates AMR through infrastructure destruction; Musmar warns wastewater and ocean surveillance data shows resistant pathogens spreading globally.
- 36:24 – 37:43
Grassroots education and consumer behavior
Speaker_0 argues bottom-up education is critical, citing grassroots movements as effective drivers of change and emphasizing the need to question prescriptions and improve diet quality.
- 37:43 – 38:50
Agricultural systems and clean water access
Speaker_0 highlights the need for resilient agricultural systems, criticizing unhealthy food systems and noting clean water access issues in the US as of 2026.
- 38:50 – 39:57
Governance, accountability, and conflict zones
Abbara stresses governance and accountability in conflict settings, contrasting higher-resource settings with northeast Syria where drought and poverty exacerbate AMR risks.
- 39:57 – 40:45
Unregulated antibiotic use in food chains
Speaker_2 describes findings from northeast Syria where human-grade antibiotics are used for animals due to cost arbitrage, leading to food chain contamination.
- 40:45 – 41:46
Regulatory reform needs
Speaker_2 calls for regulatory shifts and accountability, noting weak enforcement in places like Syria allows easy access to large amounts of antibiotics in pharmacies.
- 41:46 – 42:25
Longevity and fundamental health problems
Lori Ellis connects AMR to the longevity sector, arguing foundational health problems like clean water and antibiotic resistance must be addressed before pursuing longevity discoveries.
Claims worth verifying
Musmar states that antibacterials in clinical development dropped from 97 two years ago to only five working against critical priority bacteria.
Lori Ellis ·11:18
How to verify: Check the WHO or FDA antibiotic development pipeline reports for the relevant years to compare the number of antibacterials in clinical trials against critical priority pathogens. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Musmar claims it takes close to 10 years for an antibiotic to reach the shelves (FDA approval process).
Unidentified speaker (speaker_0) ·27:00
How to verify: Review FDA Center for Drug Evaluation and Research (CDER) data on average drug development timelines, specifically for antibiotics, to verify the duration from discovery to market approval. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Abbara estimates that 80% of AMR mortality occurs in low-resource settings.
Unidentified speaker (speaker_2) ·20:19
How to verify: Search for global AMR mortality studies (e.g., IHME Global Burden of Disease study) to find the percentage of deaths attributed to AMR in low- vs. high-income countries. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Primary sourceMusmar states that Acinetobacter (Iraqi Bacter) has no drug that truly addresses it and has been a problem since the Iraq War.
Unidentified speaker (speaker_0) ·13:29
How to verify: Consult CDC or WHO reports on Acinetobacter baumannii resistance and available therapeutic options, and review historical medical literature on infections during the Iraq War. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Abbara notes there have been more than 3,000 attacks on healthcare in Ukraine.
Unidentified speaker (speaker_2) ·29:02
How to verify: Search for reports from the World Health Organization (WHO) or the UN Office for the Coordination of Humanitarian Affairs (OCHA) regarding attacks on healthcare in Ukraine. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Musmar claims that tides are carrying resistant pathogens from sewage into fisheries and food systems, citing data from Gaza affecting Greece.
Unidentified speaker (speaker_0) ·33:35
How to verify: Search for peer-reviewed scientific studies or environmental agency reports on antibiotic-resistant bacteria in wastewater, ocean water, and seafood in the Eastern Mediterranean region. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Musmar states that the FDA process in the US takes years, similar to the UK and elsewhere.
Unidentified speaker (speaker_0) ·27:00
How to verify: Compare FDA approval timelines with those of the UK Medicines and Healthcare products Regulatory Agency (MHRA) for recent antibiotic approvals. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Abbara states that AMR contributes to more deaths than cancer, heart disease, or strokes.
Unidentified speaker (speaker_2) ·18:04
How to verify: Compare global mortality statistics from the WHO or CDC for AMR against those for cancer, cardiovascular disease, and stroke. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Primary sourceMusmar claims that venture capitalists require returns within 5 years, making AMR investments unattractive.
Unidentified speaker (speaker_0) ·25:39
How to verify: Review standard venture capital fund term sheets and lifecycle documents to confirm typical investment horizons and return expectations. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Primary sourceMusmar states that fungal infections like Valley fever are on the rise and cause significant morbidity.
Unidentified speaker (speaker_0) ·23:45
How to verify: Check CDC surveillance data for coccidioidomycosis (Valley fever) incidence rates over the last decade in the US Southwest. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Speaker_0 states that grassroots movements make a change and that top-down movement on AMR is not fast enough.
Unidentified speaker (speaker_0) ·36:24
How to verify: Review academic literature on the efficacy of grassroots advocacy in public health policy changes; compare timelines of policy adoption vs. grassroots mobilization for AMR. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Primary sourceSpeaker_0 claims that even organic produce in the US has become 'junk' or low quality.
Unidentified speaker (speaker_0) ·37:24
How to verify: Search for peer-reviewed studies or USDA reports on nutrient density trends in US organic produce between 2026 and 2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Speaker_0 asserts that access to clean water is an issue in 2026, including in some US states where apartment buildings are no longer legally guaranteed clean water.
Unidentified speaker (speaker_0) ·38:23
How to verify: Check US EPA reports or state-level housing codes and water quality regulations for 2026-2026; look for news reports on water infrastructure failures in US apartment complexes. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Speaker_2 states that in northeast Syria, antibiotics are routinely used for animals and as fertilizer with no regulation.
Unidentified speaker (speaker_2) ·39:57
How to verify: Search for academic publications or NGO reports (e.g., WHO, MSF) on agricultural practices and antibiotic use in northeast Syria post-2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Speaker_2 claims that human-grade antibiotics are often used for veterinary purposes in Syria because they are cheaper than veterinary-grade options.
Unidentified speaker (UNKNOWN) ·40:45
How to verify: Review veterinary supply chain reports or market analyses for antibiotic pricing and availability in Syria; check pharmacy sales data if available. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Speaker_2 notes that the Ministry of Health in Syria is actively trying to regulate antibiotic access, but enforcement is weak.
Unidentified speaker (speaker_2) ·40:23
How to verify: Search for Syrian Ministry of Health directives or reports on antibiotic regulation enforcement in 2026-2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Lori Ellis states that she has had conversations about longevity and believes fundamental health problems must be tackled before longevity discovery.
Lori Ellis ·41:46
How to verify: Review Lori Ellis's public statements, interviews, or newsletters from 2026-2026 regarding her views on longevity and AMR. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Do your own research
- Verify AMR mortality statistics against WHO or CDC datasets to assess the claim that AMR deaths exceed cancer or heart disease.
- Review FDA approval timelines for recent antibiotic approvals to confirm the 10-year cycle claim versus VC return horizons.
- Check wastewater surveillance data from public health agencies for evidence of global resistant pathogen spread via environmental vectors.
- Analyze pharmaceutical company filings for R&D allocation in antibiotics versus oncology to assess market prioritization.
- Investigate agricultural antibiotic usage regulations in Syria and other conflict zones to verify claims of human-grade drug diversion.
- Assess the economic impact of AMR on healthcare systems and insurance models to evaluate the 'morbidity' argument.
- Review the performance of 'value-based pricing' models for antibiotics in countries like the UK or Sweden to test viability.
- Examine the quality control standards for 'organic' produce in the US to verify claims of nutritional degradation.
Full transcriptexpand
0:00Unidentified speaker (speaker_0): One Health is the interaction of water, environment, animal, human, agriculture. And it's this perpetual cycle of one augments the other, or it's it's almost like a feedback cycle, right? So when we're talking about solutions, we need to look at everything altogether.
0:18Unidentified speaker (UNKNOWN): Hello,
0:19Lori Ellis: my name is Lori Ellis, and I am your host of Open Door Salon, where global healthcare is discussed by the people who build, fund, and fight for it.
0:37Unidentified speaker (UNKNOWN): And
0:38Lori Ellis: today we're gonna talk about AMR and the pipeline that seems to be ignored. And with me, we're just gonna get into it. With me, I have Jamana Musmar, Muzmar, founder and senior consultant, advisors of global health, CEO, AMR Strategic Coalition, and Dr. Ula Abarra, consultant in clinical infectious diseases and general internal medicine, London Imperial College. Well, one, Jamana and Ula, thank you so much for being here. And I have lots of questions. Uh lots of questions because we have Global Health is becoming more and more well it always was very important, but now it seems to be almost at a critical level, at least in my opinion. One of the things I want to start with a conversation is that the case in Russia set off alarms within days before anyone knew what had actually happened. What did that reaction tell you about how prepared we actually are
1:43Unidentified speaker (UNKNOWN): and
1:43Lori Ellis: what do we need to worry about?
1:45Unidentified speaker (speaker_0): It's been a few weeks since that happened, as and as you can imagine, that's already out of sight and out of mind because it's human behavior to have the attention span of just a few minutes until something else comes through. Unfortunately, it is also normal for us. to be more of a react uh a reactive rather than proactive society. And that's one of the biggest problems, which is why policy wise, we constantly push for a reminder and an awareness of doing things now because it is forgotten tomorrow. So even though that was a warning sign, uh especially for us here in the United States and elsewhere all over the world. it's already become yesterday's news and nobody's paying as much attention to it because there are other events that are happening. So having a resilient system in place that has a level of global collaboration and coordination and data communication to be able to have these safeguards in place is of just just
2:47critical. We need to be threat agnostic when it comes to these things. so that when they do happen, we already have a system in place. And as of today, we do not have a system in place. We try to data share, we try to work together, but there's just too many political tensions and other barriers that prevent us from doing that. So that's why the time is always now, not later. This isn't a tomorrow problem, it's an always problem.
3:13Unidentified speaker (UNKNOWN): Uh
3:14Unidentified speaker (speaker_2): so I would second that. And I would also say that globally, because of the outbreaks that we're seeing around the world, uh we can see I think there's more and more interest and um um so I'm gonna restart that. So um so so Jumana, I would agree with what you said, and actually what it also showed me is just how much interest there is. in both emerging and re-emerging infectious diseases, but also the perceived threats that might arise when these suspected or confirmed uh cases arise. And I think on the back of the COVID-19 pandemic, people are really quite sensitised. So whether it's the hantavirus outbreak that was seen a few months ago or with the Ebola, which obviously is a significant Ebola outbreak, or the concern about Yasinia pestis in Russia, people are very, very sensitized and I think quite reactive. It also tells us that we're probably, even in the global north, not as prepared as we might like to be should these threats arrive on our borders. And this takes international cohesion.
4:26collaboration, this takes investment, this takes political will and leadership to make sure all populations all around the world do feel protected and are protected. And also, very importantly, that we veer away from misinformation, disinformation, withholding information, and making sure that we are very able to strongly collaborate and strongly share the right information. in the right ways, in ways that are timely, and make sure that potential threats are addressed early and in a way that is free from politicization, but one that really puts communities at the heart of all the decisions that are being made.
5:07Lori Ellis: And then I I have another question um, which we haven't mentioned yet, and and it may maybe be not on the radar. Claude had recently. reported, or Anthropic reported, that at least there was one uh prompt on how to make a virus more harmful. And so we're seeing AI being used for drug discovery. And it's just logical
5:31Unidentified speaker (UNKNOWN): that
5:31Lori Ellis: it would also be used for harm. How important is to have this threat in place
5:36Unidentified speaker (UNKNOWN): b I
5:37Lori Ellis: would say before we really start putting more money into drug discovery?
5:42Unidentified speaker (speaker_0): So let me just comment at a baseline. We have threats that are alive and well today. These are naturally evolving threats. A big part of, and this is what I work with Dr. Abada on, in terms of the as part of this conflict working group with the International Society of Antimicrobial Chemotherapy.
6:02Unidentified speaker (UNKNOWN): The
6:02Unidentified speaker (speaker_0): threats, they're different ranges of threats. You've got man-made, you've got intentional, you've got naturally occurring, you've got it's it's just a nice hodgepodge of problems that we face on a daily basis. Conflict and the progression of disease that is ongoing today from conflict is something that is unfortunately pushing the fast-forward fast forward button on the progression of antimicrobial resistance. around the world. And this is something that Dr. Abara is an expert on and has all the data and the science behind it. I just speak the policy. And so our attention to it's just compounded by the fact that you have these man-made and also bad intent uh actors, or we call them bad actors, that are trying to push a different level. of of threat and risk on top of everything else just makes things worse. So that it so what I what I'm trying to say is we cannot focus on
7:03the unknown and what could be when we need to actually focus also on what is happening today and what is going around today that threatens our relationship resilience, our ability to have safeguard our children, safeguard our food security, and all the other facets of day-to-day life. And which is why we do need a very threat agnostic approach to these things, because there's just it's it's a range of issues that can happen. And now with the advancement of artificial intelligence. and the potential that it could provide, yes, we are magnifying the ability of something either dual use being manufactured or being able to uh uh fast track the development of something because we have these much smarter machine learning platforms that are able to do that for us, it's no longer just us thinking about. things, it's having this animated
8:06device that's able to do things at a much faster pace and also think of things that we haven't thought of. But at the same time, we can't lose track of what's going on today. What's going on today is the level of resistant pathogens increasing at an insane rate and getting transmitted throughout the world. through natural channels and portals. So I'll I'll pause on that and have Dr. Abada elaborate a little bit more on what I'm saying.
8:34Unidentified speaker (speaker_2): Now, and I hear what you're saying about AI. I'm still discovering AI and how to use it for good. But of course, we can also imagine that people might be harnessing it for other reasons. I would also observe over the last 10, 15, 20 years, we're potentially seeing more and more emerge. emerging and re-emerging infections, including ones that we had control over, vaccine-preventable ones like measles, like diphtheria being very, very obvious and concerning ones. So, yes, there could well be new threats related to AI, but also in the line of work that I do, when we look at conflict, Conflicts, when we look at crises, when we look at multi-crisises, multi-crisis, when we look at climate change, the changes in vector. biology, increasing resistance both for antimicrobial resistance, but also antimalarial resistance, insecticide resistance, which is affecting some of the vectors that we deal with. So we're seeing significant increases in known infections. So known demivirus virus and other arboviruses, we're seeing more concerning and widespread outbreaks. And to be crystal clear, sadly it's mostly affecting the most marginalized, so
9:44not those of us in comparatively functioning public health systems, particularly in the global north, but really the most disenfranchised. And so absolutely there are threats which relate to AI and I'd also argue threats that already exist even prior to the full potential of AI. And I don't know that we've seen what AI is going to do, both in the outbreak and infectious diseases world, but also outside of it. But again, I think what that comes back to is focusing on communities, focusing on information, focusing on leadership, focusing on preparedness, detection, and outbreak responses. And perhaps it is getting more complicated than it was before the age of widespread internet use and climate change and the other factors that we've mentioned. And also, sadly, the breakdowns, which is contributing to significant conflicts and significant changes in the way that conflict is being conducted.
10:45Often in urban, heavily crowded populations, uh often with direct targeting. not only of whole hospitals, but also of water and sanitation and electricity and everything else that goes alongside. So I think that's a long-winded way to say absolutely it could well be a threat, but I'd also argue in the very immediate we're also seeing lots of other compounding threats.
11:08Unidentified speaker (UNKNOWN): So
11:08Lori Ellis: understanding m all of the different threats that we're having, one, what makes it so difficult? And this is a low. loaded question, to get collaborative leadership. But then also, why is it so difficult to get it funded right now? When I looked at the stats and and saw that, you know, the antibacterials and clinical developments down from 97 two years ago, and only five work, at least one of its critical prior priority bacteria. I'm confused at this point of why, particularly because it's on a global scale.
11:48Unidentified speaker (speaker_0): No, that's a great question. And that's something that, you know, as as being having been involved in the messaging when it comes to antimicrobial resistant policy, the problem I see having been in this for over a decade. right now, strictly from the policy side of things and translating that science into messaging, is the fact that we've always looked at antimicrobial resistance as it's an enterprise. It's very difficult to kind of wrap your mind around it because we're not talking about a single pathogen issue. It's very easy for society to focus on Ebola. Ebola is ugly, and the images that are associated with it impact human reaction and your feelings towards it. When you talk about hantivirus and what happened on the cruise ship, well, we relayed in high-income countries because for us, we're like, oh my god, I take a cruise. You know, what could happen to me in addition to noravirus? So you're talking about single pathogen issues. When we talk about the enterprise of antimicrobial resistance,
12:50Unidentified speaker (UNKNOWN): it's
12:50Unidentified speaker (speaker_0): not just one bug. We're talking about super bugs in general, right? And a lot of them have and all of them have impacts in different areas. And so that is part of the reason why funding unfortunately can't hasn't gone towards a single pathogen problem. So for example, acinidobacteria. Acinetobacter, resistant Acinidobacter, also known as Iraqi Bacter, is ubiquitous within the Middle East, within North Africa, and other parts of the world. It's become what's called a hospital-acquired infection, which is it's just there. And the problem is there's no drug for it that truly addresses it. And that's been a problem since the days of the Iraq War because it's part of society. right? And so that's not something that we pay attention to here because it doesn't, it's not as prominent. So for decision makers, it's an over there problem, right? But it's not an over there problem anymore because of globalization. And then you've got other pathogens that I'm sure Dr. Abada can speak to that threaten cancer treatment, that the threaten procedures, that threaten uh uh deliberate. deliveries in hospitals. It's just there's and they're and they're all very different. So paying attention to all of these
14:09different ones is overwhelming when it comes to where you focus your funding, which is why we're trying very hard, at least for US policy here, to bring awareness to what AMR is, which is antimicrobial resistance, what superbugs are,
14:25Unidentified speaker (UNKNOWN): and
14:25Unidentified speaker (speaker_0): the need to fund the entire platform. Because these companies are running, they're they're going bankrupt because they're focused on that niche area. You can't have a single drug that addresses everything. That makes the problem worse. You need to develop a range of drugs, right? To be specific to each and every pathogen so that we don't develop more resistance. Um, and so it's important to understand. the entire enterprise what the issue is as AMR as a problem, so that we can focus the funding on each of those particular drugs that are needed because it should be one drug, one bug. But unfortunately, we're not that the the market isn't set up for that because we've been using what are called broad spectrum antibiotics that treat several bugs through one pill. So it's it's really a market issue, it's an awareness issue, and we have to change what we've been doing and how we've been doing business and the economics of it to be able to address it.
15:28Unidentified speaker (UNKNOWN): So
15:28Unidentified speaker (speaker_0): I I hope that answers your question a little bit.
15:31Unidentified speaker (speaker_2): Absolutely. I always wonder about antimicrobial resistance. One, and German has heard me say this before, is a vastly imperfect term. So outside of the medical community, I think probably also within the medical community, people are not so familiar with exactly what we mean or what we're referring to, let alone patients themselves and communities. And for me, that's a problem. It therefore also means that potentially policymakers, those in charge of the purse strings, those in charge of funding research, those in in charge of funding organisations that tackle antimicrobial resistance, they may also not understand it or not necessarily understand the biggest priorities within the AMR world. I'd also say beyond that is why I find antimicrobial resistance, particularly in settings of conflict, endlessly fascinating. because it's very cross-cutting there's multiple factors that feed into this conversation and there's multiple ways that we need to tackle it I like that complexity but obviously when you're talking policy and when you're talking to populations people much prefer simplicity
16:44Unidentified speaker (UNKNOWN): and
16:44Lori Ellis: environment
16:46Unidentified speaker (speaker_2): one anti virus one virus one antiviral one bacteria one antibacterial, um, one pathogen, one vaccine. Um, and I think it's this complexity that perhaps makes it a bit harder to understand and tackle. Um there's also within us, and when we're talking when we talk about antimicrobial resistance, we often are referring to bacteria, but actually we're talking about all microbes, so parasitic infections, protozoal infections, even tuberculosis, viral infections, fungal infections. And so once you start coming into that, I think it adds a lot more complexity. And every single one of these is a massive field of study and response.
17:28Unidentified speaker (UNKNOWN): The
17:29Unidentified speaker (speaker_2): other thing I wonder about with antimicrobial resistance is it's relatively insiduous, Insidious, perhaps more invisible, certainly more invisible than diphtheria, Ebola. even influenza. So some of the common things that we might might see and treat. So I think for both patients and healthcare workers, it's perhaps a little bit more nebulous than some of the other more concrete pathogens that are more visible to us. I'd also say the other thing is, and as a reminder, so antimicrobial resistance. contributes to the death and suffering of more people than many other diseases around the world. So, for example, cancer, for example, heart disease, or for example, strokes. And the other important thing about AMR is we're probably vastly undercounting Counting when we look at mortality. And the reason for that is if you have a cancer, the cancer itself can kill you. But also if you, because you're back and forth to hospital, because you're taking lots of antibacterials, you could develop antimicrobial resistance, and you may therefore end up with sepsis and a poor outcome relating to an infection. And in these populations, so
18:44patients with cancer, patients needing dialysis, patients who use hospitals frequently, people who go to intensive care. The very sad fact is we're seeing more and more pathogens, particularly bacteria that are so resistant that actually very little treatment that we can offer. Or if there is treatment, it's to the cost of thousands of dollars per week, and you still don't know if the outcome is going to be favorable, favourable and often have a wider side effect profile than some of the other antibiotics that we use. And we also know many parts of the world affected by conflict, poverty, broken healthcare system. These antibiotics and antimicrobials are so expensive that they're out of reach for at least 99% of the population. Going back to the production or the discovery of new antimicrobials. just a flag: if you're a drug company, you're investing millions, if not more. And the return may not be so great. But remember, if you're investing in drugs for oncology or non-communicable diseases, you may get far better returns, especially if you're aiming at a global
19:59north market. If you look at the AMR data. on mortality globally, I think the latest estimate is something like 80% occurs in low resource settings. So the burden is disproportionately in low resource settings compared to some of the higher income settings or the global north settings, where patients may be able to afford the very expensive drugs that you as a drug company are producing.
20:24Unidentified speaker (speaker_0): Agreed, but and just to add to that, it's a value issue, right? We are not putting the same value. So right now, let's say you need to take a Z pack, because you you have an infection, right? And so when you go buy that Z Pak, you're paying pennies based on the insurance that you have. And I'm speaking only relative to high income countries. In lower income countries, unfortunately, the availability of antibiotics are very ubiquitous and easily accessible. You don't need a prescription anymore. So the value of what that is to have that kind of, and I would call it a placebo effect, because if you get a sniffle, you've got a virus, right? But you go buy that augmentin and you feel better all of a sudden in a few days, so you immediately make that connection. And because it's so cheap, it's an easy fix. But what we've done as a society is that we've progressively made the situation worse because of this behavior and this practice. So part of fixing the market and the demand that's there is also associating the value of what these antibiotics are and increasing what they the value of them so that listen, we all know that pharmaceutical companies need to make a profit. It's a business, and we need to just come to terms with that. And I know that a lot of people look at big pharma as the boogie. boogeyman that makes a lot of money. But when it comes to antibiotic
21:42development, antimicrobial development to address these resistant bugs, they're not making any money, which is why they're filing for bankruptcy and we're investing millions of dollars, at least here in the United States, through government subsidized programs, incubators, and all these other things, only for them not to reach the market and it doesn't get into the hands. And even when we have a product that caters to lower income countries, we can't even get it over there because it is too expensive for them to be able to buy it and access it and also manufacture it to begin with. So there's a lot of problems, and there are proposed solutions to it. The problem overall is the awareness, at least, from and I'm over. oversimplifying the heck out of this right now. The overarching problem is that we are not valuing it as a product that is packaged with the other um areas of healthcare. And I'm speaking only in terms of the human health side of things. So for example, oncology needs to make sure that they have a demand for whatever those. uh novel antibiotics are to safeguard their patients as part of
22:55the treatment plan. That creates a demand. Surgery, same situation. So you've got all these different fields that need to also be pushing the narrative, part and parcel of their treatment plans and the risks that they know are associated. And like Dr. Abada said, we don't have the data to back it up because if somebody has cancer and they die of sepsis, the death certificate is going to associate it with cancer, not the sepsis, because that was their primary ideology. And we and that's why our numbers aren't adding up that way. The other part I want to speak to is the morbidity factor. You know, fungal infections are on the rise, right? Valley fever is a massive issue on the West Coast and the United States and the South Coast. Southwest in particular. And although people don't die from it as quickly as what our numbers, you know, what we like to pay attention to, everyone looks at mortality, the suffering, the morbidity, the loss of lives, quality of lives, jobs, um the uh the the amount of time that they spend in the hospital. the number of medications that
24:05they have to go through for to find some sort of of solution is is astronomical. And so it's important for us to also account for the morbidity factor and the pain and suffering that people go through, not just the mortality, because the the the the system isn't set up in a way to be able to quantify that. And we're hopefully going in that direction so that we have the numbers to show that there are costs associated, there is an economic loss associated with that as well. And so it that all boils back down to the value factor. Are we valuing these drugs as much as we should? For them to have a market demand and supply as a result.
24:50Unidentified speaker (UNKNOWN): A
24:50Lori Ellis: lot of the these companies that are going when they're seeking funding, I mean, obviously there's federal funding and there's a lot of problems with policies.
24:58Unidentified speaker (UNKNOWN): But
24:58Lori Ellis: there's also impact vestors that they're going out to. And you did simplify it,
25:03Unidentified speaker (UNKNOWN): but
25:03Lori Ellis: a lot of times with investors, you have to simplify it, as in it's a 10-page deck to get their attention. So as these companies are approaching them, one, what would you suggest? to approach, which you have already started to discuss a little bit, but what would you suggest for investors to be looking for? And how to explain how important all of this is?
25:27Unidentified speaker (speaker_0): The problem with venture capitalists is that they need to have their return on investment immediately and immediately being within the next five years. With the way the system is set up right now. it is not profitable, which is why we don't have a market that caters to venture capitals that are usually the biggest, you know, uh uh uh cap you know funders when it comes to these companies. If it's a phage company, let's say, or if it's an antibiotic developer, or a diagnostic, even, which is a whole other situation because we need the right diagnostics in place as well to let us know that this bug is resistant and this is where time, this the time sensitivity is part of it. Um, and so unfortunately, with the way the market currently is, it's it's not gonna be uh attractive to them to invest in that way because, and I personally think this, I think this is a long-term investment that will show dividends because of. the increase. And the problem is that once the numbers do increase and the levels of resistance become more ubiquitous and become part and parcel of society, it's already too late. Because, as was
26:41mentioned, A, our system is not set up to quickly kind of turn around antibiotics in record time. It takes a lot of investment, it takes a lot. of time. And the FDA process is, at least in the United States, and I'm sure similarly in the UK and elsewhere, we're talking years. It takes close to 10 years for something to actually reach the shelves at a CVS or anywhere else. So, how much time would you like to wait? How much time do you need when if you need it right now?
27:14Unidentified speaker (UNKNOWN): And then
27:14Unidentified speaker (speaker_0): that's why we need to be more proactive rather than reactive, to have a value set on these things to start and maintain a system.
27:23Unidentified speaker (UNKNOWN): So
27:23Lori Ellis: I'm just thinking of you know the wars, the conflicts that are having. I'm thinking about the data centers introducing new pathogens. I'm thinking about all of that right now. And I'm also thinking about 10 years and oh my God. You know uh 10 ten years and yeah like it it I I I was aware of it before, but let's be honest, it just uh hit me in the face right now. Um please. As I process.
27:49Unidentified speaker (speaker_2): I I think you're hitting the nail on the head because we are at crisis point now when it comes to AMR and conflict and crises, and we're seeing more and more conflict crises. Um I've worked for the last 15 years or so, particularly on the Syrian conflict, but also in terms of other conflicts. And I remember on Syria, like every year, we think it can't get worse, but sadly every year something happens and it gets worse. Not just from the conflict, by the way, and the horrors that you see in conflict, the use of chemical weapons, the cross-red lines, the bombing of hospitals, the deliberate. destruction of civilian infrastructure. But on top of that, economic crises and inflation, earthquakes, the COVID-19 pandemic, vaccine hesitancy and mistrust that leads to widespread outbreaks. And I'm going to stress again, it's always the most vulnerable, particularly those with intersectional marginalization, that are the most affected. And very sadly every year, And I think we just need to look to the last two or three years, not just with the very latest attacks on Iran and Gazza, but also what's happened in Ukraine. There's been more than 3,000
29:02attacks on healthcare in Ukraine. In Sudan, it's one of the most devastating conflicts that we don't hear enough about, with extreme suffering among the populations. And beyond that, we're seeing warfare. change. One of the most devastating things that we've seen this year, even more than we've seen in the last two or three years, of the um, I'm going to say the deliberate targeting of civilians and civilian infrastructure with increasing impunity, including the destruction of microbiology laboratories and attempts to attack laboratories which are housing some of the most dangerous pathogens anywhere. around the world, anthrax being an important one, Nicenia pestis being another important one, is also the use of drone warfare. So again, we're going back to the use of technology not for the power of good, but for increased suffering. And this is changing the way decisions are made in conflict. And it's changing the impacts on civilians, on healthcare. and what it is that we can or can't do in
30:05these situations. I think it's important for us not to lose hope, and whether it's now or in five years or 10 years, those of us working in the AMR conflict space, and by the way, it's a growing space, and one of the things that the ISAC working group is very aware of is um, and some of some of my colleagues uh in the group and outside of it have been working on this for 15 plus years, back to Iraqi Bacter
30:31Unidentified speaker (UNKNOWN): in
30:31Unidentified speaker (speaker_2): the Iraqi conflict, uh Lebanon, uh Syria, and elsewhere. But one of the important roles that we have is to keep the conversation going, keep people engaged, um, keep the theoretical side and the practical side moving. So on one hand, we're increasing education and knowledge about such an important and growing threat. But on the other hand, making sure that while we're doing that is also to put act to put our actions in place so that there are the right therapeutics, that there are the right diagnostics. But also very, very importantly it's so neglected is making sure that we put prevent the development of infections and we prevent the transmission of infections. And that's particularly concentrated in concrete settings, that's particularly concentrated in healthcare settings. So making sure that we're putting these safeguards in place. So I hear what you say, and um we are in crisis point now. I worry what the world will look like in five years or two. ten years. But hopefully we'll see better political changes in that time.
31:44Hopefully, we will see more recognition of um and perhaps more accountability very importantly in terms of the impact that conflict has on healthcare pathogens, antimicrobial resistance, and onwards.
32:00Unidentified speaker (speaker_0): And I I want to add also in terms of you know, Dr. Abara mentioned One Health. And just to define, One Health is the interaction of water, environment, animal, human, agriculture. And it's this perpetual cycle of one augments the other, or it's it's almost like a feedback cycle, right? So when we're talking about solutions, we need to look at everything altogether. And within the context of war in particular, she had mentioned chemical warfare in particular, you know, and and just to just to emphasize what she's saying, there are no rules of war anymore. When you have the uh targeted bombing of these healthcare systems, laboratories, just basic needs, um, what you're creating is an additional. um uh Pandora's box of issues that are further augmented. So you've got, and just to kind of again simplify the picture when it comes to one health, the sewage water mixed with heavy metals, mixed with chemicals, mixed with decomposing bodies, mixed with animals and agriculture that has rotted. I just I'm trying to draw
33:15a picture here. Festers into the ground in a way that also leads to erosion into the seas. There's data that shows that the tides all over the world are carrying a lot of these resistant pathogens. And in fact, they're showing up in fisheries and they're showing up in people's food systems. The problem is that we need to open our ears and our eyes to see what we want to see and hear, right? And so doing the hear no evil, see no evil, speak no evil doesn't help anyone, right? And currently, unfortunately, that's part of the practice that we have day to day. But we have to be aware of these things because it does impact. And there is data showing that, particularly from Gaza, where you've got a lot of these washing into the shores, one of their neighboring countries is Greece. And Greece, in particular, particular,'s is pretty primary food source are fisheries and seafood. And so it is showing that a lot of these resistant pathogens are in aquaculture that's being farmed there. And so there needs we have some data. There's a little bit, and that little bit is really scary. And so I think we need to also pay attention to the little bit that's there before we get to a lot of it because people aren't investing into the surveillance to show what the you know to confirm and validate what bigger numbers look like.
34:34Because even the tiny bit that we see that's coming out of the sewage water, that's in the region, that's in the seas, that's already making its way all over the world is already scary enough. So I think we can easily extrapolate to say that once we actually have uh appropriate. wastewater surveillance and ocean water surveillance data, the picture is going to be amplified tremendously. And so we need to pay attention to this stuff and think about it. Because even when I talk about bird migration and how it actually from the flyaways they stop from Asia to the Middle East and pick up and go to Europe, that's also spreading resistant pathways. pathogens on the way. And so that's that's the one health picture of things that even though if you think of a solution for one area, you gotta think about the entire system and how it actually interacts because we are one globe. There are no visas for everyone. Everyone talks to each other, the system interacts in a way that is just natural. So we have to think about that process.
35:37Lori Ellis: Well yeah, I was loving um exactly what Jamana was saying because one of the things that is
35:42Unidentified speaker (UNKNOWN): in
35:42Lori Ellis: the United States there's this d longevity um movement and a lot of money's being tossed in there.
35:49Unidentified speaker (speaker_0): Right.
35:49Lori Ellis: But with everything that you're saying right now, I certainly do not want to live longer or to a thousand years old, which is what's going on now. If I'm basically drinking sewage water and eating food that has chemicals in it, that that that's that's my initial response to it. So taking away what are the some of the ch I would say one or two, because we're not gonna solve everything right now, changes that you see either on a policy level or a funding level or even on education level.
36:24Unidentified speaker (speaker_0): To me, the education level is is the most important. right now because we're not seeing fast enough movement from the top down, so it's got to be the bottom up, which has really had which has been our approach. We've seen a lot of evidence that grassroots movements do make a change. And I'm not going to compare AMR to climate change because that took way too long for us to even recognize, and we're still not there. We're still doing things that harm. the environment and are increasing our global warming issues that we have in the world. We need our kids to understand. We need our families to know and question that if you go to the doctor and they say, Oh, you're taking antibiotic, or if you go to your pharmacy and you have a sniffle, take an antibiotic, I say, Do I need it? Do I have to have it? So the recognition needs to come from the person within to really understand. it. And that's why, even this whole wellness movement and higher income countries, it's very privileged for us to want to live longer, have better skin, and all that. And so
37:24let's take advantage of that. Do you want to take something and do you want to eat better food? Because what I've found in the groceries living in the United States right now is that the quality's gone down. I buy organic because I am privileged enough to be able to afford it. And even the organic produce that's out there has been junk.
37:43Unidentified speaker (UNKNOWN): So
37:43Unidentified speaker (speaker_0): if we're talking about eating well, we need to be able to solve the problem at its base. And this is where getting our microbiomes stronger, making sure that the agriculture that we are are our uh I'm trying to think of the word. words. Sorry, I'm getting a brain fart right now. Um, the agricultural system that we have is resilient enough and healthy enough to give us the food that we need for our kids and ourselves and generations to come. Because as of today, we've created a system that is completely unhealthy. And that's with us being living in a higher income sort of status, right? So you can only imagine what the rest of the world is dealing with. And even access to clean water in itself is still an issue today in 2026.
38:33Unidentified speaker (UNKNOWN): I know that's
38:34Unidentified speaker (speaker_0): a problem.
38:35Unidentified speaker (UNKNOWN): I
38:35Lori Ellis: also mentioned that uh there's certain states that it's no longer a guarantee, even in a country like the United States, that you
38:42Unidentified speaker (UNKNOWN): can
38:42Lori Ellis: have clean water. And they've reduced polities that if you're in an apartment building, you don't necessarily you it's not against the law now.
38:49Unidentified speaker (speaker_0): Right? So
38:50Unidentified speaker (speaker_2): I definitely think it's the uh bottom up, but also there has to be the role for the top down. Um what I've learned over the last uh few years of working in the conflict space, but also in the infectious diseases and outbreaks space in conflict settings, is the importance of governance and accountability. And I think that's what you alluded to with the comment about the apartment blocks. Um but it's also what we deal with in conflict settings. One of the impacts is actually the breakdown of governance and the rule of law. And some of my colleagues have done an awful lot of work on this, and you can expand it to any aspect of healthcare, health systems, but also daily life. And for the most part,
39:37Unidentified speaker (UNKNOWN): in
39:37Unidentified speaker (speaker_2): global north settings or higher. high resource settings, there is some sort of governance, there is some sort of accountability. It is being fractured, unfortunately, in certain countries, but this is certainly not the case in some of the settings I work in. One of my MPH students did a really excellent piece of work on One Health and AMR in the northeast of Syria, so an area that's affected by uh drought, conflict. poverty, disenfranchisement, displacement. And what he found from speaking to people in agriculture and veterinary and healthcare is profound. It's the routine use of antibiotics for animals or the routine use of antibiotics as fertilizer with no regulation, no accountability. and actually this is coming into our food chains and affecting human health. Because in countries like Syria and the Ministry of Health is actively trying to regulate this, you can walk into a pharmacy and buy large amounts of antibiotics if it's available. The quality, of course, may be very variable.
40:45Unidentified speaker (UNKNOWN): But
40:45Unidentified speaker (speaker_2): you could be a veterinary worker or you may be an agriculturist. and because to buy veterinary grade antibiotics is more expensive, you might actually just prefer to go and buy some antibiotics for human health and use that instead. There's also large lots of practices that can impact the development of AMR and infection in some of these settings. So I would say the other thing that needs to shift is the regulatory aspect. aspects, the governance aspects, the accountability um that needs to sit there both at the very local level but also going up to the very senior levels.
41:25Lori Ellis: Wow. Um this has definitely been eye opening as in I knew, like I I knew, right? But I just didn't fully get how bad it really is. Um and I know we've just scratched the surface, and so I think we're gonna have to have more conversations about it.
41:45Unidentified speaker (UNKNOWN): Um
41:46Lori Ellis: and I think honestly one of the reasons why I want to is I've had conversations about longevity.
41:52Unidentified speaker (UNKNOWN): I
41:53Lori Ellis: don't think you can have a conversation or you can have a longevity space without tackling these fundamental problems before you even go into that discovery land.
42:07Unidentified speaker (speaker_2): That's
42:07Unidentified speaker (UNKNOWN): just one
42:08Lori Ellis: comment.
42:09Unidentified speaker (speaker_3): Hey, I have a newsletter on Substack, and you can read the seven key takeaways for this episode in all of them. If you like our content, or if you want to get in contact with me, subscribe.